Buy PE-22-28 Online
PE-22-28 is a seven-amino-acid peptide derived from the larger spadin peptide sequence and developed as a more stable TREK-1 potassium-channel inhibitor. Research has focused primarily on depression, neurogenesis, and neuronal signaling.
Product Information
PE-22-28 was designed after researchers identified a shorter portion of spadin retaining strong TREK-1 inhibitory activity. Laboratory research demonstrated substantially greater TREK-1 affinity than the parent spadin molecule.
How Does It Work?
PE-22-28 inhibits the TREK-1 potassium channel, a pathway implicated in neuronal excitability, mood regulation, and antidepressant responses.
Benefits
Antidepressant Research
PE-22-28 has produced antidepressant-like effects in animal models, making it an important experimental candidate for studying rapid-acting antidepressant mechanisms.
Neurogenesis Research
TREK-1 inhibition has been associated with signaling that influences neuronal plasticity and neurogenesis, providing another mechanism of interest for PE-22-28 research.
Strong TREK-1 Activity
Laboratory testing found PE-22-28 to inhibit human TREK-1 with an IC50 of approximately 0.12 nM, substantially stronger than the parent spadin peptide in the same experimental system.
Peptide Stability Research
PE-22-28 was specifically designed to improve upon the short duration and stability limitations of spadin, making it a useful research tool for studying TREK-1 biology.
Side Effects
There is insufficient human safety information to establish a reliable side-effect profile. Experimental reports may include headache, dizziness, fatigue, nausea, and sleep changes.
Dosage
There is no established human dosing protocol for PE-22-28. Online research-peptide sources commonly discuss approximately 100–500 mcg per administration, but these figures are community-derived and not supported by controlled human dose-ranging studies.
Research Reference
Djillani A, Pietri M, Moreno S, et al. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Frontiers in Pharmacology. 2017;8:643. PMID: 28955242.
Purerawz Disclaimer
Purerawz does not sell, manufacture, stock, dispense, or directly supply any of the products discussed on this website. Purerawz is an independent information and affiliate platform. Where available, links may direct readers to independent third-party providers, and Purerawz may receive a commission from qualifying purchases at no additional cost to the reader.
The information provided is for educational and informational purposes only. Dosage figures may reflect published research protocols, historical clinical use, or reported community practices and should not be interpreted as personalized medical instructions. Research findings—particularly those from animal, cellular, or small early-stage studies—do not establish that a product is safe or effective for every individual or condition.
